# Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK

> **NCT05873062** · PHASE1 · COMPLETED · sponsor: **Autifony Therapeutics Limited** · enrollment: 6 (actual)

## Conditions studied

- Myoclonus Epilepsies, Progressive

## Interventions

- **DRUG:** AUT00201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05873062
- **Lead sponsor:** Autifony Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-12
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05873062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05873062, "Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05873062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*